- Home
- VTGN vs MRKR Comparison
VTGN vs MRKR Comparison
Compare VTGN & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | MRKR |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 23.0M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | VTGN | MRKR |
|---|---|---|
| Price | $0.64 | $1.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $0.90 | ★ $11.25 |
| AVG Volume (30 Days) | ★ 546.3K | 115.2K |
| Earning Date | 02-12-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.81 |
| 52 Week High | $5.14 | $4.07 |
Technical Indicators
Market Signals| Indicator | VTGN | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 40.44 |
| Support Level | $0.63 | $0.83 |
| Resistance Level | $0.65 | $1.44 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 69.00 | 20.00 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.